Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Clinical Research and Equipment Industry Analysis

UpdatedMay 29, 2026
DataAggregated Company Financials
Companies63
  • 7D7.8%
  • 3M-2.2%
  • 1Y13.9%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 1.6%, with Thermo Fisher Scientific leading the way with a 1.0% gain. This takes the industry's 12 month performance to a gain of 7.3%. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 29 May 2026US$550.4bUS$150.6bUS$13.8b38.1x40x3.7x
Sun, 26 Apr 2026US$546.2bUS$149.0bUS$14.4b30.5x38x3.7x
Tue, 24 Mar 2026US$542.7bUS$147.8bUS$14.0b35.2x38.7x3.7x
Thu, 19 Feb 2026US$581.2bUS$147.7bUS$13.9b34.3x41.8x3.9x
Sat, 17 Jan 2026US$704.2bUS$145.8bUS$12.4b36.8x57x4.8x
Mon, 15 Dec 2025US$656.7bUS$145.8bUS$12.5b34.4x52.6x4.5x
Wed, 12 Nov 2025US$641.2bUS$145.7bUS$12.2b35.4x52.8x4.4x
Fri, 10 Oct 2025US$622.9bUS$144.3bUS$14.6b32.6x42.8x4.3x
Sun, 07 Sep 2025US$576.5bUS$144.3bUS$14.6b29.9x39.6x4x
Tue, 05 Aug 2025US$552.8bUS$144.0bUS$13.0b32.1x42.4x3.8x
Thu, 03 Jul 2025US$541.5bUS$142.9bUS$9.1b36.3x59.3x3.8x
Sat, 31 May 2025US$507.5bUS$142.9bUS$9.2b32.4x54.9x3.6x
Mon, 28 Apr 2025US$519.3bUS$142.5bUS$10.0b37.5x52x3.6x
Wed, 26 Mar 2025US$601.4bUS$143.0bUS$9.9b38.9x60.8x4.2x
Fri, 21 Feb 2025US$620.2bUS$143.3bUS$9.6b38.4x64.4x4.3x
Sun, 19 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Tue, 17 Dec 2024US$666.2bUS$142.4bUS$10.2b45.5x65.2x4.7x
Thu, 14 Nov 2024US$683.4bUS$142.4bUS$10.3b45x66.4x4.8x
Sat, 12 Oct 2024US$724.1bUS$141.8bUS$8.5b37.7x85.3x5.1x
Mon, 09 Sep 2024US$731.3bUS$141.8bUS$8.5b37.5x86.1x5.2x
Wed, 07 Aug 2024US$722.7bUS$141.0bUS$11.3b36.7x64.2x5.1x
Fri, 05 Jul 2024US$662.1bUS$141.3bUS$12.2b38.5x54.4x4.7x
Sun, 02 Jun 2024US$702.1bUS$141.3bUS$12.4b38.2x56.5x5x
Tue, 30 Apr 2024US$709.6bUS$141.6bUS$12.7b39.6x55.8x5x
Thu, 28 Mar 2024US$742.5bUS$142.1bUS$12.8b43.9x58x5.2x
Sat, 24 Feb 2024US$729.7bUS$142.1bUS$12.4b43.7x58.8x5.1x
Mon, 22 Jan 2024US$691.1bUS$153.8bUS$14.2b35.9x48.8x4.5x
Wed, 20 Dec 2023US$697.4bUS$153.8bUS$14.2b37.4x49x4.5x
Fri, 17 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Sun, 15 Oct 2023US$629.3bUS$154.6bUS$11.2b33.2x56.2x4.1x
Tue, 12 Sep 2023US$690.0bUS$154.6bUS$11.2b32.2x61.6x4.5x
Thu, 10 Aug 2023US$729.3bUS$154.6bUS$11.3b30.2x64.6x4.7x
Sat, 08 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Mon, 05 Jun 2023US$683.1bUS$152.4bUS$12.5b29.1x54.6x4.5x
Price to Earnings Ratio

54.6x


Total Market Cap: US$683.1bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Clinical Research and Equipment Industry Price to Earnings3Y Average 56.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.8x which is lower than its 3-year average PE of 56.5x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 3.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Comparison

How does U.S. Clinical Research and Equipment compare with similar industries?

US Market1.83%
Healthcare1.81%
Life Sciences7.85%
Clinical Research and Equipment7.85%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$487.228.4%
+US$14.1b		20.7%PE26.4x
A Agilent TechnologiesUS$135.3817.9%
+US$5.8b		19.5%PE27x
DHR DanaherUS$180.634.2%
+US$5.2b		-5.2%PE34.8x
WAT WatersUS$366.677.5%
+US$2.5b		3.2%PE80.1x
IQV IQVIA HoldingsUS$181.097.8%
+US$2.2b		28.4%PE21.8x

Latest News

ICLR
US$136.80
ICON
7D
17.4%
1Y
4.4%
CDT
US$0.95
CDT Equity
7D
-22.1%
1Y
-99.9%
A
US$135.38
Agilent Technologies
7D
17.9%
1Y
19.5%
ILMN
US$158.70
Illumina
7D
9.6%
1Y
88.3%
LFCR
US$4.97
Lifecore Biomedical
7D
-0.2%
1Y
-27.4%
Narrative Update • May 28

LFCR: CDMO Site Transfers And 2028 Ramps Will Support Future Upside

Narrative Update: Lifecore Biomedical Analysts have adjusted their average price target for Lifecore Biomedical toward $5 to $5.50, reflecting mixed recent research in which one firm lifted its target by $0.50 while another reduced its target by $3.50. The firms cited the timing of commercial ramps and a slightly later potential breakout year as key drivers.
MLAB
US$103.10
Mesa Laboratories
7D
-5.5%
1Y
-1.5%
TMO
US$487.22
Thermo Fisher Scientific
7D
8.4%
1Y
20.7%
Narrative Update • May 26

TMO: High Conviction Tools Demand And New Platforms Will Drive Performance

Thermo Fisher Scientific's analyst fair value estimate is updated from $648.28 to $611.56 as analysts weigh modestly different assumptions for discount rate, revenue growth, profit margins and future P/E, alongside mixed research commentary that includes fresh additions to high conviction lists and several price target cuts across the Street. Analyst Commentary Recent research on Thermo Fisher shows a mix of optimism and caution, with fresh inclusion in a high conviction list on one side and several price target cuts and neutral ratings on the other.
IQV
US$181.09
IQVIA Holdings
7D
7.8%
1Y
28.4%
RPID
US$2.02
Rapid Micro Biosystems
7D
-2.4%
1Y
-40.1%
DHR
US$180.63
Danaher
7D
4.2%
1Y
-5.2%
Narrative Update • May 19

DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple

Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.
WAT
US$366.67
Waters
7D
7.5%
1Y
3.2%
Narrative Update • May 18

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).
ALMR
US$19.76
Alamar Biosciences
7D
-10.2%
1Y
n/a
MTD
US$1,163.50
Mettler-Toledo International
7D
6.7%
1Y
-0.8%
Narrative Update • May 15

MTD: 2026 Local Currency Sales Outlook Will Drive Future Upside

Analysts have trimmed their price target for Mettler-Toledo International from about $1,488 to roughly $1,345, citing updated assumptions that include slightly different revenue growth, profit margin, discount rate, and future P/E expectations. What's in the News Mettler-Toledo International issued new earnings guidance for the second quarter of 2026, indicating an anticipated local currency sales increase of approximately 3% (company guidance).
CSBR
US$5.85
Champions Oncology
7D
-1.7%
1Y
-5.3%